Mayne Pharma’s Scheme Meeting to Proceed Amidst Cosette’s Termination Notice

Mayne Pharma Group ( (AU:MYX) ) has provided an announcement.

Mayne Pharma Group Limited has announced that the Supreme Court of New South Wales has approved the distribution of a Supplementary Scheme Booklet to its shareholders, following a notice from Cosette Pharmaceuticals intending to terminate a previous scheme implementation deed. Despite this development, the scheduled Scheme Meeting on 18 June 2025 will proceed as planned, with the company’s directors unanimously recommending shareholders vote in favor of the proposed scheme of arrangement, barring any superior proposals.

The most recent analyst rating on (AU:MYX) stock is a Buy with a A$7.09 price target. To see the full list of analyst forecasts on Mayne Pharma Group stock, see the AU:MYX Stock Forecast page.

More about Mayne Pharma Group

Mayne Pharma is an ASX-listed specialty pharmaceutical company that focuses on commercializing novel pharmaceuticals, primarily in dermatology and women’s health. The company also offers contract development and manufacturing services globally and has a strong history of innovation in oral drug delivery systems.

Average Trading Volume: 906,491

Technical Sentiment Signal: Strong Sell

Current Market Cap: A$400.5M

For detailed information about MYX stock, go to TipRanks’ Stock Analysis page.